NCT06309290 Prehabilitation With Resistance-exercise Training for Breast Cancer Neoadjuvant Therapy
| NCT ID | NCT06309290 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidad de La Frontera |
| Condition | Prehabilitation |
| Study Type | INTERVENTIONAL |
| Enrollment | 68 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 68 participants in total. It began in 2025-01-01 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Breast cancer stands as the foremost cause of cancer-related deaths among women worldwide, with the highest incidence of any cancer type. The choice of therapeutic interventions hinges upon factors like cancer stage, cell subtype, and tumor size. Consequently, individuals with more aggressive tumors, such as HER+2 and Triple Negative, or larger tumors often undergo neoadjuvant chemotherapy before breast surgery. However, these anticancer treatments come with side effects like cancer-related fatigue, reduced functional capacity, and changes in body composition, notably skeletal muscle atrophy. Skeletal muscle loss correlates with heightened mortality rates, cardiotoxicity, and diminished quality of life, underscoring the need for early therapeutic interventions. One such promising strategy is prehabilitation, which involves resistance-exercise training aimed at bolstering skeletal muscle mass from the outset of the disease, even preceding breast surgery. Resistance-exercise training has shown favorable effects on women undergoing adjuvant therapy or survivors of breast cancer, however, its molecular and clinical effects in women with breast cancer undergoing neoadjuvant therapy are unknown.
Eligibility Criteria
Inclusion Criteria: * Postmenopausal women with breast cancer in stages I, II and III with luminal breast tumor, HER2+ or TNBC * Indication for neoadjuvant chemotherapy * Candidates for curative breast surgery * Body mass index: 18.5 \<BMI \<30 kg/m2 * Sedentary (does not perform scheduled or planned physical activity ≥ 2 times a week) * Willingness to participate in the study and follow the proposed prehabilitation scheme. Exclusion Criteria: * Present comorbidities that interact with the metabolism and mobility of the muscles of the body and that do not allow the (safe) performance of strength exercises (e.g., debilitating arthritis, all neurological disorders, paralysis, among others). * Severe or uncontrolled cardiovascular disease, cardiac ejection fraction less than 50% * Previous antineoplastic treatment * Use of nutritional supplements (leucine, glutamine, casein, whey protein, fatty acids and creatine).
Contact & Investigator
Gabriel N Marzuca-Nassr, PT, MSc, PhD
PRINCIPAL INVESTIGATOR
Universidad de La Frontera
Frequently Asked Questions
Who can join the NCT06309290 clinical trial?
This trial is open to female participants only, studying Prehabilitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06309290 currently recruiting?
Yes, NCT06309290 is actively recruiting participants. Contact the research team at klga.macarena.artigas@gmail.com for enrollment information.
Where is the NCT06309290 trial being conducted?
This trial is being conducted at Santiago, Chile, Temuco, Chile.
Who is sponsoring the NCT06309290 clinical trial?
NCT06309290 is sponsored by Universidad de La Frontera. The principal investigator is Gabriel N Marzuca-Nassr, PT, MSc, PhD at Universidad de La Frontera. The trial plans to enroll 68 participants.